371 related articles for article (PubMed ID: 37880715)
1. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy.
Bulliard Y; Andersson BS; Baysal MA; Damiano J; Tsimberidou AM
J Hematol Oncol; 2023 Oct; 16(1):108. PubMed ID: 37880715
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
Yang Z; Wang Y
Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
[TBL] [Abstract][Full Text] [Related]
3. Engineering the next generation of CAR-NK immunotherapies.
Biederstädt A; Rezvani K
Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
[TBL] [Abstract][Full Text] [Related]
4. A metabolic switch to memory CAR T cells: Implications for cancer treatment.
Rostamian H; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Pawelek JM; Hadjati J; Brown CE; Mirzaei HR
Cancer Lett; 2021 Mar; 500():107-118. PubMed ID: 33290868
[TBL] [Abstract][Full Text] [Related]
5. T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies.
Tang L; Zhang Y; Hu Y; Mei H
Biomed Res Int; 2021; 2021():6616391. PubMed ID: 33728333
[TBL] [Abstract][Full Text] [Related]
6. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
Ho M; Zanwar S; Paludo J
Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
[TBL] [Abstract][Full Text] [Related]
8. Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies.
Kampouri E; Little JS; Rejeski K; Manuel O; Hammond SP; Hill JA
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14157. PubMed ID: 37787373
[TBL] [Abstract][Full Text] [Related]
9. Exhaustion of CAR T cells: potential causes and solutions.
Kouro T; Himuro H; Sasada T
J Transl Med; 2022 May; 20(1):239. PubMed ID: 35606821
[TBL] [Abstract][Full Text] [Related]
10. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
[TBL] [Abstract][Full Text] [Related]
11. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic engineering for optimal chimeric antigen receptor T cell therapy.
Ito Y; Kagoya Y
Cancer Sci; 2022 Nov; 113(11):3664-3671. PubMed ID: 36000807
[TBL] [Abstract][Full Text] [Related]
13. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.
Roselli E; Faramand R; Davila ML
J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33463538
[TBL] [Abstract][Full Text] [Related]
14. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
15. Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies.
Zhang G; Deng L; Lu H; Zhang W
Int J Clin Pharm; 2024 Feb; 46(1):186-194. PubMed ID: 38087131
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
Shen C; Zhang Z; Zhang Y
Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
[TBL] [Abstract][Full Text] [Related]
17. [Development of next-generation chimeric antigen receptor-engineered T-cell therapy].
Kagoya Y
Rinsho Ketsueki; 2022; 63(9):1290-1297. PubMed ID: 36198555
[TBL] [Abstract][Full Text] [Related]
18. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
Sun W; Liang AB; Huang H; Huang XJ
Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
[TBL] [Abstract][Full Text] [Related]
19. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy.
Li W; Pan X; Chen L; Cui H; Mo S; Pan Y; Shen Y; Shi M; Wu J; Luo F; Liu J; Li N
Front Immunol; 2023; 14():1186383. PubMed ID: 37342333
[TBL] [Abstract][Full Text] [Related]
20. Leukapheresis for CAR-T cell production and therapy.
Pessach I; Nagler A
Transfus Apher Sci; 2023 Dec; 62(6):103828. PubMed ID: 37838564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
